Six cancers had downregulated CDKN2C expressions, namely breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), kidney chromophobe (KICH), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), and uterine corpus endometrial carcinoma (UCEC) (p < 0.05; Fig. 5A). This evidence concerns the gene CDKN2C and prostate adenocarcinoma.